Using a murine model of AD that accurately mimics multiple facets of human neurodegenerative diseases, we evaluated the therapeutic capacity of targeting the NLRP3 inflammasome using a novel and highly selective brain penetrant inhibitor. This evidence concerns the gene NLRP3 and Alzheimer disease.